Cytomed Therapeutics Limited Stock Performance
| GDTC Stock | 1.54 0.02 1.32% |
The firm shows a Beta (market volatility) of 1.7, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CytoMed Therapeutics will likely underperform. At this point, CytoMed Therapeutics has a negative expected return of -0.24%. Please make sure to confirm CytoMed Therapeutics' accumulation distribution, and the relationship between the potential upside and day median price , to decide if CytoMed Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CytoMed Therapeutics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
1 | CytoMed makes cash bid for potential acquisition of TC BioPharm Limiteds relevant assets | 10/14/2025 |
2 | CytoMed Therapeutics Limited stock outlook for YEAR - 2025 Historical Comparison Reliable Intraday Trade Plans - newser.com | 10/29/2025 |
3 | Applying Wyckoff theory to CytoMed Therapeutics Limited stock - Trade Entry Report AI Enhanced Trading Alerts - newser.com | 11/05/2025 |
4 | Is CytoMed Therapeutics Limited stock a fit for income portfolios - Jobs Report Verified Chart Pattern Signals - newser.com | 11/11/2025 |
5 | Why CytoMed Therapeutics Limited stock could benefit from AI revolution - Market Sentiment Summary Risk Controlled Daily Trade Plans - Fundao Cultural do Par | 11/14/2025 |
6 | Is CytoMed Therapeutics Limited stock vulnerable to regulatory risks - Bond Market Real-Time Stock Entry Alerts - newser.com | 11/17/2025 |
7 | Can CytoMed Therapeutics Limited stock resist broad market declines - Gold Moves Real-Time Chart Breakout Alerts - newser.com | 11/20/2025 |
8 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session | 12/09/2025 |
9 | Why CytoMed Therapeutics Limited stock could outperform in 2025 - Analyst Downgrade Daily Chart Pattern Signals - DonanmHaber | 12/19/2025 |
| Begin Period Cash Flow | 4.7 M | |
| Total Cashflows From Investing Activities | 494.6 K |
CytoMed Therapeutics Relative Risk vs. Return Landscape
If you would invest 197.00 in CytoMed Therapeutics Limited on September 25, 2025 and sell it today you would lose (43.00) from holding CytoMed Therapeutics Limited or give up 21.83% of portfolio value over 90 days. CytoMed Therapeutics Limited is currently does not generate positive expected returns and assumes 5.3967% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than CytoMed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CytoMed Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytoMed Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CytoMed Therapeutics Limited, and traders can use it to determine the average amount a CytoMed Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0447
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GDTC |
Based on monthly moving average CytoMed Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CytoMed Therapeutics by adding CytoMed Therapeutics to a well-diversified portfolio.
CytoMed Therapeutics Fundamentals Growth
CytoMed Stock prices reflect investors' perceptions of the future prospects and financial health of CytoMed Therapeutics, and CytoMed Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytoMed Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (4.52) % | ||||
| Current Valuation | 15.94 M | ||||
| Shares Outstanding | 11.73 M | ||||
| Price To Book | 3.20 X | ||||
| Price To Sales | 24.36 X | ||||
| Revenue | 52.01 K | ||||
| Gross Profit | 675.25 K | ||||
| EBITDA | (1.79 M) | ||||
| Net Income | (1.84 M) | ||||
| Total Debt | 339.2 K | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (1.69 M) | ||||
| Earnings Per Share | (0.25) X | ||||
| Market Capitalization | 22.53 M | ||||
| Total Asset | 7.37 M | ||||
| Retained Earnings | (10.87 M) | ||||
| Working Capital | 5.39 M | ||||
About CytoMed Therapeutics Performance
By analyzing CytoMed Therapeutics' fundamental ratios, stakeholders can gain valuable insights into CytoMed Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CytoMed Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytoMed Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 9.9 K | 9.4 K | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.29) | (0.30) |
Things to note about CytoMed Therapeutics performance evaluation
Checking the ongoing alerts about CytoMed Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytoMed Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CytoMed Therapeutics generated a negative expected return over the last 90 days | |
| CytoMed Therapeutics has high historical volatility and very poor performance | |
| CytoMed Therapeutics may become a speculative penny stock | |
| The company reported the previous year's revenue of 52.01 K. Net Loss for the year was (1.84 M) with profit before overhead, payroll, taxes, and interest of 675.25 K. | |
| CytoMed Therapeutics generates negative cash flow from operations | |
| CytoMed Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 67.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Why CytoMed Therapeutics Limited stock could outperform in 2025 - Analyst Downgrade Daily Chart Pattern Signals - DonanmHaber |
- Analyzing CytoMed Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytoMed Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CytoMed Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CytoMed Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytoMed Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CytoMed Therapeutics' stock. These opinions can provide insight into CytoMed Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CytoMed Stock analysis
When running CytoMed Therapeutics' price analysis, check to measure CytoMed Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytoMed Therapeutics is operating at the current time. Most of CytoMed Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytoMed Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytoMed Therapeutics' price. Additionally, you may evaluate how the addition of CytoMed Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |